Allocetra Holds 12-Month Knee OA Benefit; Phase IIb Data Due Mid-2027
ENLV is trading near its 52-week low of $1.73 (9.8% above the low) on elevated volume (1.9× avg).
Summary
Enlivex reported 12-month topline data from the Phase IIa stage of its Allocetra knee osteoarthritis trial, showing a durable response in patients 64 and older. At one year, 79.2% of Allocetra patients met the OMERACT-OARSI responder criteria versus 47.6% on placebo (p=0.027), a 66% relative improvement consistent with the 3- and 6-month readouts, when the responder rate was 80% higher for Allocetra than placebo at 3 months (p=0.019) and 39% higher at 6 months (p=0.168). WOMAC pain and function differences versus placebo narrowed by 12 months and lost statistical significance (-12.2 points, p=0.113 for pain; -13.1 points, p=0.067 for function), though the direction still favored treatment, after pain differences of -17.5 points at 3 months (p=0.004) and -15.4 points at 6 months (p=0.012) and function differences of -19.3 points at 3 months (p=0.0008) and -19.5 points at 6 months (p=0.0008); no treatment-related serious adverse events were seen, with adverse events predominantly transient, mild to moderate local knee reactions. The double-blind, randomized, placebo-controlled, multi-centered Phase IIa stage randomized and treated 134 patients, and patient age was the strongest predictor of treatment response, with the treatment effect increasing with age; improvements in patient-reported outcomes were supported by objective physical performance tests and exploratory serum biomarker and imaging analyses, and a single three-injection treatment cycle produced a sustained response through one year. The 12-month data will be presented at ACR Convergence on November 8, 2026, and support the ongoing Phase IIb trial in the same age-related population, with topline results guided for the end of Q2 2027. This is a clinical win for a micro-cap that has been under severe pressure: a 1-for-16 reverse split took effect October 27 and the company disclosed a Nasdaq delisting notice the same day, alongside an October cost-cutting plan that cut about 60% of the workforce. The Phase IIb readout by end-Q2 2027 is the next hard clinical milestone.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — The 12-month data will be presented at ACR Convergence on November 8, 2026, and Enlivex guides Phase IIb topline data in the same population by end of Q2 2027.
- Earlier Readouts — At 3 months the responder rate was 80% higher for Allocetra than placebo (p=0.019) and at 6 months 39% higher (p=0.168). WOMAC pain difference vs placebo was -17.5 points at 3 months (p=0.004) and -15.4 points at 6 months (p=0.012); function difference was -19.3 points (p=0.0008) and -19.5 points (p=0.0008).
- Age Effect — Patient age was the strongest predictor of treatment response, with treatment effect increasing with age.
- Supporting Measures — Improvements in patient-reported outcomes were supported by objective physical performance tests and exploratory serum biomarker and imaging analyses.
- Safety — Adverse events were predominantly transient, mild to moderate local knee reactions; no treatment-related serious adverse events observed.
- Trial Design — The Phase IIa stage was double-blind, randomized, placebo-controlled and multi-centered, with 134 patients randomized and treated.
- Dosing — A single three-injection treatment cycle of Allocetra produced a sustained treatment response through one year.
- Presentation Details — Poster title: Durable Clinical Efficacy of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis: Age-Related Effect Through One Year. Abstract ID 24454477; Poster Session A (0632–0644): Osteoarthritis – Clinical Poster A.
All 10 details
- 3 months: 80% higher responder rate for Allocetra than placebo (p=0.019); 6 months: 39% higher (p=0.168)
- WOMAC pain difference vs placebo: -17.5 points at 3 months (p=0.004), -15.4 points at 6 months (p=0.012)
- WOMAC function difference vs placebo: -19.3 points at 3 months (p=0.0008), -19.5 points at 6 months (p=0.0008)
- Patient age was the strongest predictor of treatment response, with treatment effect increasing with age
- Improvements in patient-reported outcomes were supported by objective physical performance tests and exploratory serum biomarker and imaging analyses
- Adverse events were predominantly transient, mild to moderate local knee reactions; no treatment-related serious adverse events observed
- Phase IIa stage: double-blind, randomized, placebo-controlled, multi-centered; 134 patients randomized and treated
- Poster title: Durable Clinical Efficacy of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis: Age-Related Effect Through One Year
- Abstract ID 24454477; Poster Session A (0632–0644): Osteoarthritis – Clinical Poster A
- A single three-injection treatment cycle of Allocetra produced a sustained treatment response through one year
At the time of this announcement, ENLV was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $1.73 to $434.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.